Advancing DTx

DTx Value Assessment & Integration

Building Blocks for Scalable Patient Access

Healthcare decision makers (HCDM) play a critical role in providing patients with access to high-quality, clinically validated digital therapeutics. Given the growth of the DTx industry over the last decade and lack of frameworks defining what “good” looks like, many HCDMs have needed to develop their own methods to evaluate DTx products.

DTA’s DTx Value Assessment & Integration Guide provides HCDMs and DTx manufacturers with an initial framework to assess DTx products, their value, and impact in real-world settings. With ongoing engagement from patients, clinicians, payors, and policy makers, this Guide will continue to be updated to ensure ongoing relevance in this quickly evolving ecosystem.

Download the Value Assessment & Integration Guide

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Target Audiences

This Guide is designed to assist healthcare decision makers in assessing and integrating DTx products into clinical use settings. Target audiences for this Guide include:

Advisory Teams
Patient advisory boards, caregivers, and practicing care team members
Authorizing Clinicians
Clinicians qualified to authorize patient use of the product
Clinical Support Teams
Administrative representatives and clinical practice implementation teams
Compliance Teams
Legal, regulatory, privacy, and security teams
End Users
Patients, caregivers, clinicians, and care teams
Payors, employers, health plan strategy and budgetary approval teams
Policy Makers
Government entities, HTA bodies, and public payors
Product Access Teams
Technical infrastructure, implementation, and support teams
Product Evaluation Teams
P&T committees, formulary developers, and innovation divisions

Dynamic Framework With International Applicability

Healthcare Decision Makers
  • A consistent set of criteria to rely on when evaluating DTx products
  • A baseline framework to use when seeking information from DTx manufacturers
  • A guide that can serve as a starter evaluation process for healthcare systems
  • A process that can be used in parallel with, or to refine, existing evaluation systems
  • An initial benchmarking system to compare various DTx products to each other
  • A framework to assess the legitimacy and impact of DTx products for patient care
  • A process to determine how to best implement DTx products in practice
  • A tool to assess DTx appropriateness for individual patient use
  • A guide to determine how to leverage real-world outcomes in patient care
DTx Manufacturers
  • A rubric to pre-populate and distribute to appropriate entities (in particular, the DTx Manufacturer version of this Guide, which is currently reserved for DTA member companies)
  • A framework that provides HCDMs, policy makers, and clinicians with information on product design, impact, and utilization
  • A more consistent set of expectations to meet across all clinical use environments

This Guide is intended to serve as a conversation starter between HCDMs and DTx manufacturers. It does not provide a definitive decision for HCDMs on whether or not to use a specific product in practice, and does not imply that a product has or has not met all necessary qualifications for clinical use. DTA invites HCDMs to join our efforts in developing the next iterations of this framework.

Integrating DTx Products into Clinical Settings

The following topics covered in this Guide may benefit patients, clinicians, policy makers, and payors from around the world as they increasingly assess and use DTx therapies at scale:

Supporting the industry’s continuing evolution

This Guide was developed through a collaborative process, with input from DTA members, as well as clinicians, payors, and others involved in manufacturing, evaluating, supporting, and utilizing DTx products.

As the DTx ecosystem continues to rapidly evolve, this framework will be updated to ensure ongoing relevance with input from all key stakeholders. Please share insights with us on how you are using or implementing this Guide, or if you would like to be part of ongoing efforts.

Share Your Insights

This resource is for educational purposes only and is not intended as legal advice to individual companies. Payors have
differing coverage, coding, and reimbursement policies. Laws, regulations, and payor policies concerning coverage, coding,
and reimbursement are complex and are evolving rapidly. For legal advice, please consult with legal counsel.

Digital Therapeutics Alliance makes no warranty or representation regarding the completeness, accuracy, or timeliness of the
information provided and makes no guarantee of coverage or reimbursement for any digital therapeutic product. Contact the
applicable payor for specific guidance regarding coverage, coding, and reimbursement guidelines.

Join the DTA Community

Connect Now
Copyright © 2024 Digital Therapeutics Alliance™